Oruka Therapeutics (ORKA) Enterprise Value (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Enterprise Value of -$831.2 million for Q1 2026, down 138.09% year-over-year from $2.2 billion in Q1 2025, and down 148.21% quarter-over-quarter from -$334.9 million in Q4 2025.
Oruka Therapeutics (ORKA) Enterprise Value (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$831.2 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 138.09% year-over-year to -$831.2 million; the TTM figure through Mar 2026 stood at -$831.2 million (down 138.09% YoY), while the FY2025 annual figure was -$334.9 million, up 10.86% from the prior year.
- Enterprise Value for Q1 2026 stood at -$831.2 million, down from -$334.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$33.3 million in Q2 2024, with the low at -$831.2 million in Q1 2026.
- The 5-year median for Enterprise Value is -$46.4 million (2022), against an average of -$222.8 million.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value rose 26.7% in 2022, then sank 947.94% in 2024.
- Oruka Therapeutics' Enterprise Value stood at -$42.4 million in 2022, then advanced by 11.81% to -$37.4 million in 2023, then slumped by 903.57% to -$375.6 million in 2024, then rose by 10.86% to -$334.9 million in 2025, then slumped by 148.21% to -$831.2 million in 2026.
- Business Quant data shows ORKA's Enterprise Value at -$831.2 million in Q1 2026, -$334.9 million in Q4 2025, and -$756.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | -1.73 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.73 Bn |
| Mar 31, 2026 | -831.16 Mn |
| Dec 31, 2025 | -334.86 Mn |
| Sep 30, 2025 | -756.56 Mn |
| Jun 30, 2025 | -328.41 Mn |
| Mar 31, 2025 | -349.09 Mn |
| Dec 31, 2024 | -375.65 Mn |
| Sep 30, 2024 | -403.32 Mn |
| Jun 30, 2024 | -33.28 Mn |
| Mar 31, 2024 | -35.90 Mn |
| Dec 31, 2023 | -37.43 Mn |
| Sep 30, 2023 | -38.49 Mn |
| Jun 30, 2023 | -40.16 Mn |
| Mar 31, 2023 | -40.85 Mn |
| Dec 31, 2022 | -42.45 Mn |
| Sep 30, 2022 | -43.94 Mn |
| Jun 30, 2022 | -46.44 Mn |
| Mar 31, 2022 | -49.06 Mn |
| Dec 31, 2021 | -53.36 Mn |
| Sep 30, 2021 | -58.31 Mn |